Objective: To determine if aspirin (ASA) therapy reduces the incidence of pre-eclampsia in women at high risk of this condition. Study design: Randomised clinical trial. We recruited pregnant women with gestational age at randomisation <14 weeks, who satisfied the following criteria: chronic hypertension, history of severe pre-eclampsia or eclampsia or intrauterine growth retardation (IUGR) or intrauterine foetal death. Nineteen women in the no-treatment group and 16 in the ASA group were successfully followed up. Results: The mean birthweight was higher in the ASA group than in the no-treatment group (2790g (S.D. 340g) versus 2616g (S.D. 779g)), but the difference was not statistically significant. We found no statistically significant differences between the groups in the proportion of infants with birthweight below 2500g (13.3% versus 29.4%) and the number of cases with pregnancy-induced hypertension (PIH)/pre-eclampsia (31.3% versus 36.8%). Conclusion: These limited data give some support to the potential favourable effect of early treatment with ASA in pregnant women at risk of PIH and IUGR.

A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia / F. Chiaffarino, F. Parazzini, D. Paladini, B. Acaia, W. Ossola, L. Marozio, F. Facchinetti, A. Del Giudice. - In: EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY. - ISSN 0301-2115. - 112:2(2004 Feb 10), pp. 142-144. [10.1016/S0301-2115(03)00269-0]

A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia

F. Parazzini;
2004-02-10

Abstract

Objective: To determine if aspirin (ASA) therapy reduces the incidence of pre-eclampsia in women at high risk of this condition. Study design: Randomised clinical trial. We recruited pregnant women with gestational age at randomisation <14 weeks, who satisfied the following criteria: chronic hypertension, history of severe pre-eclampsia or eclampsia or intrauterine growth retardation (IUGR) or intrauterine foetal death. Nineteen women in the no-treatment group and 16 in the ASA group were successfully followed up. Results: The mean birthweight was higher in the ASA group than in the no-treatment group (2790g (S.D. 340g) versus 2616g (S.D. 779g)), but the difference was not statistically significant. We found no statistically significant differences between the groups in the proportion of infants with birthweight below 2500g (13.3% versus 29.4%) and the number of cases with pregnancy-induced hypertension (PIH)/pre-eclampsia (31.3% versus 36.8%). Conclusion: These limited data give some support to the potential favourable effect of early treatment with ASA in pregnant women at risk of PIH and IUGR.
Administration, Oral ; Probability ; Reference Values ; Drug Administration Schedule ; Dose-Response Relationship, Drug ; Chi-Square Distribution ; Humans ; Gestational Age ; Pre-Eclampsia ; Italy ; Risk Assessment ; Pregnancy, High-Risk ; Pregnancy ; Aspirin ; Maternal Age ; Adult ; Treatment Outcome ; Incidence ; Follow-Up Studies ; Female
Settore MED/40 - Ginecologia e Ostetricia
EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/207046
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 42
social impact